Brady Releases Labeling System Designed for Labs
Brady introduces Labxpert v2.0 model to fulfill labeling requirements of the lab.
Oxfordshire, UK-May 13, 2008-Brady's (
The Labxpert’s 300dpi resolution printing means that even the smallest fonts and barcodes can be printed with complete clarity and legibility. More than 140 lab-specific symbols (Greek, scientific, and safety symbols) are instantly available for added convenience. This compact, lightweight (less than 1Kg), hand-held device can produce labels 80% faster than hand-writing-and with font sizes down to 1mm, far more information can be included than on any hand-written label. The innovative “Drop, Lock, and Print” Smart Cartridge makes it quick and easy to change between different labeling jobs.
However, Brady points out that in laboratory labeling the printer, however good, is only part of the story. It is when the Labxpert is combined with the unique range of specialized label materials and print media available from Brady that a solution will be found for virtually any laboratory labeling task. Labels can be produced that will withstand the harshest environments-temperatures from liquid nitrogen (-196°C) to autoclave (+121°C), and solvents like Xylene, Ethanol, DMSO, and IPA-and that will remain intact and legible through many cycles of immersion and repeated handling. Brady Freezerbondz II labels can even be applied to already frozen surfaces.
According to Brady, the latest Labxpert v2.0 model has a USB port for easy PC connectivity, plus narrower bar codes and 10 new font sizes to fit more information on the very small labels needed for some laboratory consumables. The optional IdentiLab™ PC software has easy-to-use wizards for label creation and tools for more advanced applications such as database import, automatic text formatting, multi-label data entry, and 2-D bar codes.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025